Clinical trials: Activation, Patient
PI3K Pathway Activated Tumors
BKM120 for Patients With PI3K-activated Tumors
The purpose of this signal seeking study was is to determine whether treatment with BKM120 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study.
- Trial name
- SIGNATURE (NCT01833169)
- Testing
- BKM120
- Where
- 59 sites in United States
- Volunteers
- 146 people
- Sponsor
- Novartis Pharmaceuticals
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer
This phase I trial studies how well atezolizumab before and/or with standard of care chemoradiotherapy works in immune system activation in patients with stage IB2, II, IIIB, or IVA cervical cancer that has spread to the lymph…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB2 Cervical Cancer AJCC v8
- Trial name
- NCT03738228
- Testing
- Atezolizumab, Brachytherapy, Cisplatin
- Where
- 16 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Tumor, Solid, Gastrointestinal Cancer
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
This is an open-label, prospective phase two basket trial assessing the efficacy of ulixertinib in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies.
- Trial name
- NCT05221320
- Testing
- Ulixertinib, Hydroxychloroquine
- Where
- 9 sites in United States
- Volunteers
- 47 people
- Sponsor
- BioMed Valley Discoveries, Inc
Type 2 Diabetes Mellitus With Hypoglycemia, Aging
Prepare for Your Diabetes Care
As adults with type 2 diabetes age, they are increasingly vulnerable to treatment-related hypoglycemia and its related complications (including hospitalization and death).
- Conditions
- Type 2 Diabetes Mellitus With Hypoglycemia, Aging, Patient Activation
- Trial name
- NCT05263310
- Testing
- Prepare for Your Diabetes Care, Usual Care
- Where
- United States
- Volunteers
- 672 people
- Sponsor
- Kaiser Permanente
Liver Cirrhosis, Hepatocellular Carcinoma
Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation
The objective of this study is to evaluate feasibility and safety of the adoptive transfer of activated natural killer (NK) cells extracted from cadaveric donor liver graft perfusate for liver transplant recipients with…
- Conditions
- Liver Cirrhosis, Hepatocellular Carcinoma, Evidence of Liver Transplantation
- Trial name
- MIAMINK (NCT01147380)
- Testing
- Liver NK cell inoculation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Seigo Nishida
Type 2 Diabetes Mellitus
Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)
This was a four-period crossover study to assess the glycemic effects of a single dose of oxyntomodulin (OXM) on the glucose levels in participants with Type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01373450
- Testing
- Oxyntomodulin, Liraglutide 0.6 mg, Liraglutide 1.2 mg
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Tumor Pathway Activations Inhibited by Dovitinib
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
The purpose of this signal seeking study was to determine whether treatment with dovitinib (TKI258) demonstrated sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further…
- Trial name
- SIGNATURE (NCT01831726)
- Testing
- Dovitinib (TKI258)
- Where
- 49 sites in United States
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Pain
Patient Activation to Address Chronic Pain and Opioid Management in Primary Care
Will a primary care-based behavioral intervention for patient activation and engagement and self-management, for patients with chronic pain who are taking opioid pain medication, result in better patient outcomes than Usual Care?
- Trial name
- NCT02290223
- Testing
- Behavioral Based Treatment Model
- Where
- 2 sites in United States
- Volunteers
- 376 people
- Sponsor
- Kaiser Permanente
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.
The purpose of this study is to treat patients with locally advanced or metastatic NSCLC with a combination therapy of selumetinib and two different doses of docetaxel 75mg/m2 or 60 mg/m2 vs placebo and compare how well each dose…
- Trial name
- SELECT-2 (NCT01750281)
- Testing
- Selumetinib 75 mg, Docetaxel 75 mg/m2, Docetaxel 60 mg/m2
- Where
- 68 sites in United States, Brazil and 6 more
- Volunteers
- 212 people
- Sponsor
- AstraZeneca
Colorectal Neoplasm, Colorectal Cancer
New Individualized Therapy Trial for Metastatic Colorectal Cancer
The purpose of this study is to evaluate the safety and tolerability of imatinib mesylate in combination with panitumumab for the treatment of stage IV colorectal cancer that has spread to the liver.
- Trial name
- NITMEC (NCT00867334)
- Testing
- Imatinib mesylate and panitumumab, Standard-of-care treatment with panitumumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Inova Health Care Services
Rectal Cancer
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
The purpose of this study is to determine safety and anti-tumor immune activation generated by TG02 and Granulocyte macrophage colony stimulating factor (GM-CSF), first as monotherapy (Part I), thereafter in combination with the…
- Trial name
- NCT02933944
- Testing
- TG02-treatment, Pembrolizumab
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 6 people
- Sponsor
- Targovax ASA
HIV Infection
Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure
Many people with HIV fail to regain normal CD4 counts despite effectively suppressing HIV replication with medications. Blocking the "co-receptor" for HIV might decrease inflammation of the immune system, potentially providing an…
- Trial name
- NCT00735072
- Testing
- Maraviroc
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of California, San Francisco
Mental Disorders
Effectiveness of DECIDE in Patient-Provider Communication, Therapeutic Alliance & Care Continuation
The purpose of this study is to learn more about how patients and healthcare providers interact in order to improve shared decision making.
- Trial name
- PCORI (NCT01947283)
- Testing
- DECIDE-PA, DECIDE-PC
- Where
- 8 sites in United States
- Volunteers
- 481 people
- Sponsor
- Massachusetts General Hospital
Non-small Cell Lung Cancer
A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC
This clinical research study is being carried out in two parts, Phase 1 and Phase 2. The primary purpose of the Phase 1 portion of the study is to observe the safety of the combination of rociletinib and MPDL3280A in EGFR-mutant…
- Trial name
- NCT02630186
- Testing
- Rociletinib, MPDL3280A
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Clovis Oncology, Inc.
Stage IIIB Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma
QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)
Phase II study to determine the effects of aNK infusions in combination with ALT-803 in patients with stage III (IIIB) or stage (IV) merkel cell carcinoma (MCC).
- Trial name
- NCT02465957
- Testing
- aNK (NK-92), aNK (NK-92) + N-803
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- ImmunityBio, Inc.
End Stage Renal Disease
Safety and Dose Finding Study of Xigris in Hemodialysis Patients
The purpose of the study is to assess the safety of Xigris (Drotrecogin alfa) as an anticoagulant at different dose levels during dialysis treatment in patients with End Stage Renal Disease (ESRD).
- Trial name
- Xigris1003 (NCT01227187)
- Testing
- Drotrecogin alfa activated (Xigris)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- George Washington University
Locally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
This phase Ib/II trial studies the side effects and best dose of CMP-001 and how well it works when given together with INCAGN01949 in treating patients with stage IV pancreatic cancer and other cancers except melanoma.
- Conditions
- Locally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT04387071
- Testing
- Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949, VLP-encapsulated TLR9 Agonist CMP-001
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- University of Southern California
Triple Negative Breast Cancer
A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer
The current study is designed to evaluate the efficacy and safety of AL101 monotherapy in subjects with Notch-activated recurrent or metastatic TNBC; Notch activation will be determined by a Next Generation Sequencing (NGS) test.
- Trial name
- TENACITY (NCT04461600)
- Testing
- AL101
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 18 people
- Sponsor
- Ayala Pharmaceuticals, Inc,
Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
This randomized phase III trial studies ibrutinib to see how well it works compared to placebo when given before and after stem cell transplant in treating patients with diffuse large B-cell lymphoma that has returned after a…
- Trial name
- NCT02443077
- Testing
- Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carmustine
- Where
- 281 sites in United States, Saudi Arabia
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Diabetes
Diabetes Outcomes and Unmet Resources
This study will refine and test the effectiveness of CareAvenue, an automated e-health tool that informs and activates patients with uncontrolled diabetes to take steps in accessing resources and engaging in self-care.
- Trial name
- NCT03950973
- Testing
- CareAvenue, Guest Assistance Program
- Where
- United States
- Volunteers
- 667 people
- Sponsor
- University of Michigan